RIGEL PHARMACEUTICALS INC (RIGL)       1.79  +0.02 (+1.13%)

1.79  +0.02 (+1.13%)

US7665596034 - Common Stock - After market: 1.82 +0.03 (+1.68%)


Fundamental Rating

1

Overall RIGL gets a fundamental rating of 1 out of 10. We evaluated RIGL against 641 industry peers in the Biotechnology industry. Both the profitability and financial health of RIGL have multiple concerns. While showing a medium growth rate, RIGL is valued expensive at the moment.

Note: RIGL has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

0

RIGL has a very weak Piotroski-F score of 1.00. This is an indication of health and profitability issues for RIGL.

VS Industry

Valuation

Valuation Rating

0

The Price/Earnings Ratio is negative for RIGL. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RIGL. No positive earnings are expected for the next year.
VS Industry

Growth

Growth Rating

4

Based on estimates for the next 5 years, RIGL will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.15% on average per year.
The Revenue has been growing by 48.88% on average over the past 5 years. This is a very strong growth!
Based on estimates for the next 5 years, RIGL will show a small growth in Revenue. The Revenue will grow by 6.93% on average per year.

RIGL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -433.33%.
Looking at the last year, RIGL shows a very negative growth in Revenue. The Revenue has decreased by -39.32% in the last year.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -433.33% -367.04% -54.97% -10.37% 14.15%
Revenue48.88% 49.68% -39.32% -39.39% -10.5% -3.23% 6.93%

Health

Health Rating

2

A Current Ratio of 2.34 indicates that RIGL has no problem at all paying its short term obligations.
A Quick Ratio of 2.19 indicates that RIGL has no problem at all paying its short term obligations.
When comparing the Current Ratio of RIGL to the average industry Current Ratio of 6.18, RIGL is less able to pay its short term obligations than its industry peers. 82% of its industry peers have a better Current Ratio.
When comparing the Quick Ratio of RIGL to the average industry Current Ratio of 6.05, RIGL is less able to pay its short term obligations than its industry peers. 81% of its industry peers have a better Quick Ratio.

Based on the Altman-Z score of -16.11, we must say that RIGL is in the distress zone and has some risk of bankruptcy.
When comparing the Altman-Z score of RIGL to the average industry Altman-Z score of -0.10, RIGL is less financially healthy than its industry peers. 90% of its industry peers have a better Altman-Z score.
The Piotroski-F score of RIGL is 1.00. This is a very weak score and indicates problems in health and profitability for RIGL.
VS Industry

Quick Ratio (2.19) VS Industry: 19% outperformed.

0.04
84.53

Current Ratio (2.34) VS Industry: 18% outperformed.

0.08
85.09

Altman-Z (-16.11) VS Industry: 10% outperformed.

-2,801.75
658.20

Dividend

Dividend Rating

0

RIGL does not give a dividend.

RIGEL PHARMACEUTICALS INC1.79

NASDAQ:RIGL (2/3/2023, 7:05:13 PM)+0.02 (+1.13%)

After market: 1.82 +0.03 (+1.68%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-03 2022-11-03/amc Earnings (Next) 02-27 2023-02-27/amc
Inst Owners 73.1% Inst Owner Change -1.59%
Ins Owners 1.26% Ins Owner Change 6.58%
Market Cap 309.38M Analysts 76.92
Price Target 3.74 (108.94%)

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP N/A
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) 2 Avg EPS beat(2) 27.93%
Min EPS beat(2) 19.78% Max EPS beat(2) 36.08%
EPS beat(4) 3 Avg EPS beat(4) 10.44%
Min EPS beat(4) -14.26% Max EPS beat(4) 36.08%
Revenue beat(2) 1 Avg Revenue beat(2) 10.38%
Min Revenue beat(2) -2.83% Max Revenue beat(2) 23.59%
Revenue beat(4) 1 Avg Revenue beat(4) 1.41%
Min Revenue beat(4) -8.63% Max Revenue beat(4) 23.59%
PT rev (1m) 0% PT rev (3m) -3.02%
EPS NQ rev (1m) 19.3% EPS NQ rev (3m) 13.14%
EPS NY rev (1m) 0% EPS NY rev (3m) 1.07%
Revenue NQ rev (1m) 29.2% Revenue NQ rev (3m) 21.81%
Revenue NY rev (1m) 0% Revenue NY rev (3m) -2.22%

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.46
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM) -0.48 EY N/A
EPS(NY) -0.26 Fwd EY N/A
FCF(TTM) -0.41 FCFY N/A
OCF(TTM) -0.41 OCFY N/A
SpS 0.52 BVpS -0.11
TBVpS -0.11 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM 97.88%
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y -0.02% GM growth 5Y N/A
F-Score 1 Asset Turnover 0.77

Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.84%
Profit Quality N/A
Current Ratio 2.34
Quick Ratio 2.19
Altman-Z -16.11
F-Score 1 WACC 9.2%
ROIC/WACC N/A Cap/Depr(3y) 148.71%
Cap/Depr(5y) 133.66% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y -433.33% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 8.33%
EPS Next Y -367.04% EPS Next 2Y -54.97%
EPS Next 3Y -10.37% EPS Next 5Y 14.15%
Revenue growth 1Y -39.32% Revenue growth 3Y 49.68%
Revenue growth 5Y 48.88% Revenue growth Q2Q 4.02%
Revenue Next Year -39.39% Revenue Next 2Y -10.5%
Revenue Next 3Y -3.23% Revenue Next 5Y 6.93%
EBIT growth 1Y -662.66% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year -552.17%
EBIT Next 3Y -15.15% EBIT Next 5Y N/A
FCF growth 1Y -49.65% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y -53.34%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA